BioNxt Solutions Secures Key European Patent for Its Drug Delivery Platform

BioNxt's European patent for its sublingual Cladribin thin-film tech takes effect March 2026, offering broad protection for treating MS and other diseases until 2043.

A significant milestone in BioNxt Solutions' intellectual property strategy is set to be realized. The company's European patent for its sublingual Cladribin thin-film technology will officially come into force on March 11, 2026, establishing legal protection for the proprietary process in up to 39 countries.

A Broad and Valuable Patent

Granted by the European Patent Office under number 4539857, this patent safeguards BioNxt's unique method for administering Cladribin via a dissolvable oral film. This approach eliminates the need for swallowing or injection, a design aimed at enhancing patient compliance with treatment regimens.

The scope of the patent is notably extensive. Protection is not confined to applications for Multiple Sclerosis but extends to cover other autoimmune and neurodegenerative diseases. Myasthenia Gravis is explicitly included among the covered conditions. The patent term provides this broad protection at least until June 14, 2043.

Building a Global Intellectual Property Portfolio

This European grant complements the company's existing IP assets. A comparable patent was previously issued by the Eurasian Patent Organization for eight member states. In the United States, an accelerated "Fast-Track" procedure with the USPTO has been underway since October 2025. Concurrently, nationalization processes are progressing in Canada and other key markets.

The strength of this IP strategy is supported by preclinical evidence. In January 2026, BioNxt reported that its formulation demonstrated approximately a 40% improvement in bioavailability compared to conventional methods—a critical data point on the path toward clinical approval.

The Path Forward: Human Trials

With the European patent secured, the company's focus now shifts to transitioning its Cladribin platform from preclinical work to human bioequivalence studies. This phase represents the next major test for the technology, where it will be determined if the promising preclinical results can be successfully replicated in human subjects.